Downregulation of miRNA-21 and cancer stem cells after chemotherapy results in better outcome in breast cancer patients
作者机构:BiochemistryAll India Institute of Medical Sciences Gorakhpur IndiaGorakhpur 273008Uttar PradeshIndia Department of Radiation OncologyAll India Institute of Medical SciencesJodhpur 342005RajasthanIndia Surgical OncologyAll India Institute of Medical SciencesJodhpur 342005RajasthanIndia Department of BiochemistryAll India Institute of Medical SciencesJodhpur 342005RajasthanIndia Department of Surgical OncologyAll India Institute of Medical SciencesJodhpur 342005RajasthanIndia King George’s Medical UniversityLucknow 226003Uttar PradeshIndia
出 版 物:《World Journal of Stem Cells》 (世界干细胞杂志(英文版)(电子版))
年 卷 期:2022年第14卷第4期
页 面:310-313页
核心收录:
学科分类:0710[理学-生物学] 0831[工学-生物医学工程(可授工学、理学、医学学位)] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学]
基 金:Supported by SERB:Department of Science and Technology New Delhi No. NPDF:SERB 2015/000322
主 题:Epigenetic modification miRNA-21 Breast carcinoma Autophagy Chemotherapy Breast cancer stem cells
摘 要:Epigenetic modifications have been observed as a decline in miRNA-21 expression and breast cancer stem cell(CSC)population after 3 cycles of standard *** epigenetic response(miRNAs expression)and CSCs are also correlated in patients with Breast *** patients who tolerated chemotherapy well,miRNA-21(non-coding RNA)expression decreased significantly after three cycles of *** miRNA-21 expression in breast cancer tissue was quantified by quantitative PCR(real-time PCR)using the standard *** addition,breast CSCs(CD44+/CD24-)were also decreased in these *** miRNA-21 regulates cell division,proliferation,and autophagy of cancerous cells(as it targets phosphatase and tensin homolog/AKT/transcription factor EB/programmed cell death 4/autophagy-related protein 5 and chemotherapy also produces similar effects),thereby contributing to these ***,when all of the targets on genes have been explored by mimic miRNA,chemotherapy combined with anti-miRNA21 therapy may prove useful in the care of cancer patients.